Published: 9 June 2026
The English Chronicle Desk
The English Chronicle Online
New concerns have been raised over the safety of infant sleep products, with experts warning that babies’ lives may still be at risk due to gaps in regulation across parts of the baby sleep industry.
An investigation into the sector found that a range of widely marketed sleep aids and accessories may not meet consistent safety standards, despite being sold to new parents as tools to improve infant sleep and comfort.
Child safety specialists warned that inconsistent oversight means some products enter the market without robust testing or clear evidence of safety in real-world use.
Medical professionals emphasised that safe sleep guidance for infants is well established, but said commercial products can sometimes contradict or complicate those recommendations.
Campaigners say the industry has expanded rapidly in recent years, driven by online marketing, social media influence and growing demand from exhausted parents seeking sleep solutions.
Regulators are under pressure to strengthen oversight and close potential loopholes that allow unverified products to be sold without sufficient safety validation.
Researchers involved in the investigation said there remains a lack of standardisation in how baby sleep products are classified, tested and approved.
Parent advocacy groups have called for clearer labelling, stricter enforcement and improved public awareness of safe sleep practices.
Health experts reiterated that infants should be placed on firm, flat sleep surfaces in line with official medical guidance, warning that deviations from these recommendations can increase risk.
The findings have prompted renewed debate over how quickly regulators can respond to fast-moving consumer markets, particularly those driven by online retail platforms.
Industry representatives said many manufacturers do comply with safety standards, but acknowledged that enforcement consistency varies across jurisdictions.
Authorities are expected to review the findings and consider whether further regulatory action or updated guidance is required.



























































































